Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors.

Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R.

Redox Rep. 2003;8(6):365-70.

PMID:
14980069
2.

Clinical correlation of alteration of endogenous antioxidant-uric acid level in major depressive disorder.

Chaudhari K, Khanzode S, Khanzode S, Dakhale G, Saoji A, Sarode S.

Indian J Clin Biochem. 2010 Jan;25(1):77-81. doi: 10.1007/s12291-010-0016-z. Epub 2010 Feb 10.

3.

Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.

Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A.

Neuropsychobiology. 2004;49(4):205-9.

PMID:
15154399
4.

Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment.

Gałecki P, Szemraj J, Bieńkiewicz M, Florkowski A, Gałecka E.

Pharmacol Rep. 2009 May-Jun;61(3):436-47.

5.

Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats.

Zafir A, Banu N.

Eur J Pharmacol. 2007 Oct 15;572(1):23-31. Epub 2007 Jun 13.

PMID:
17610875
6.

Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits.

Sas K, Csete K, Vezekényi Z, Sztriha L, Vécseil L, Papp JG.

Acta Physiol Hung. 2007 Sep;94(3):167-77.

PMID:
17853768
7.
8.

A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: reversal of chronic psychosocial stress-induced increase in CRE/CREB-directed gene transcription in transgenic reporter gene mice.

Böer U, Noll C, Cierny I, Krause D, Hiemke C, Knepel W.

Eur J Pharmacol. 2010 May 10;633(1-3):33-8. doi: 10.1016/j.ejphar.2010.01.016. Epub 2010 Feb 1.

PMID:
20122921
9.

Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress.

Moretti M, Colla A, de Oliveira Balen G, dos Santos DB, Budni J, de Freitas AE, Farina M, Severo Rodrigues AL.

J Psychiatr Res. 2012 Mar;46(3):331-40. doi: 10.1016/j.jpsychires.2011.11.009. Epub 2011 Dec 9.

PMID:
22154133
10.

SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

Dell'Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D'Avino C, Dell'Osso L, Bonuccelli U.

Clin Neuropharmacol. 2001 Jul-Aug;24(4):221-7.

PMID:
11479393
11.

Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine?

Prapotnik M, Waschgler R, König P, Moll W, Conca A.

Int J Clin Pharmacol Ther. 2004 Feb;42(2):120-4.

PMID:
15180173
12.

Dopaminergic mechanism of antidepressant action in depressed patients.

Willner P, Hale AS, Argyropoulos S.

J Affect Disord. 2005 May;86(1):37-45.

PMID:
15820269
13.

Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult.

Dhami KS, Churchward MA, Baker GB, Todd KG.

Mol Cell Neurosci. 2013 Sep;56:365-74. doi: 10.1016/j.mcn.2013.07.006. Epub 2013 Jul 19.

PMID:
23876875
14.

The effect of sertraline, paroxetine, fluoxetine and escitalopram on testicular tissue and oxidative stress parameters in rats.

Erdemir F, Atilgan D, Firat F, Markoc F, Parlaktas BS, Sogut E.

Int Braz J Urol. 2014 Jan-Feb;40(1):100-8. doi: 10.1590/S1677-5538.IBJU.2014.01.15.

15.

Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules.

Lekakis J, Ikonomidis I, Papoutsi Z, Moutsatsou P, Nikolaou M, Parissis J, Kremastinos DT.

Int J Cardiol. 2010 Mar 4;139(2):150-8. doi: 10.1016/j.ijcard.2008.10.010. Epub 2008 Nov 11.

PMID:
19004511
16.

Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.

Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, Cyran C, Van Amerongen P, Lemming O, Høpfner Petersen HE.

Int Clin Psychopharmacol. 1996 Jun;11(2):129-36.

PMID:
8803650
17.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
18.
19.

Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain.

Eren I, Naziroğlu M, Demirdaş A.

Neurochem Res. 2007 Jul;32(7):1188-95. Epub 2007 Mar 31.

PMID:
17401662
20.

The relevance of oxidative stress status in first episode and recurrent depression.

Stefanescu C, Ciobica A.

J Affect Disord. 2012 Dec 20;143(1-3):34-8. doi: 10.1016/j.jad.2012.05.022. Epub 2012 Jul 25.

PMID:
22840610
Items per page

Supplemental Content

Write to the Help Desk